Supplementary Figure 1 from Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Charles J. Ryan,Mark Rosenthal,Siobhan Ng,Joshi J. Alumkal,Joel Picus,Gwénaëlle Gravis,Karim Fizazi, Fréd́eric Forget,Jean‐Pascal Machiels,Sandy Srinivas, Meifang Zhu,Rui Tang,Kelly S. Oliner,Yi‐Zhou Jiang,Elwyn Loh,Sarita Dubey,Winald R. Gerritsen

openalex（2023）

引用 0|浏览2

暂无评分

摘要

PDF file - 883K, Patient disposition by treatment group. IP, investigational product; MP, mitoxantrone and prednisone. *Patient had a decrease in hemoglobin prior to administration of IP on day 1 of cycle 1. �Patient had delays to cycles prior to cycle 12.

查看译文

关键词

targeted met inhibition,prostate cancer,biomarker analysis,mitoxantrone,castration-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要